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THE ROLE OF NEUROINFLAMMATION IN CHRONIC TRAUMATIC 
ENCEPHALOPATHY 
 
LORNA S. COLLINS 
 
ABSTRACT 
 Chronic traumatic encephalopathy (CTE) is a neurodegenerative disorder caused 
by repeated concussive or subconcussive blows to the head.  Clinically, this disease is 
characterized by cognitive dysfunction, short-term memory loss, and motor deficits.  
Pathologically, deposition of the abnormal protein tau, cerebral atrophy, and white matter 
degeneration is common.  CTE has been categorized into Stages I-IV based on increased 
severity of protein deposition and cerebral atrophy. Acutely, mild traumatic brain injury 
(TBI) damages the long white matter tracks in the corpus callosum.  In addition, it 
initiates a neuroinflammatory cascade aimed at protecting healthy tissue by clearing any 
toxic or damaging debris.  This cascade results predominantly from the activation of the 
resident immune cells of the brain, microglia.  Inflammation begins immediately and then 
subsides weeks or months after injury.  However, pathological chronic activation of 
microglia can occur that can cause cell death and degeneration.  Several studies have 
linked traumatic brain injury as well as chronic neuroinflammation to a variety of 
neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, 
amyotrophic lateral sclerosis, and chronic traumatic encephalopathy (CTE). 
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The present study quantifies the level of inflammation found in the brains of those 
diagnosed with varying stages of CTE compared to normal, healthy controls.  The 
thickness of the corpus callosum was measured to investigate the correlation between 
microglial density and white matter degeneration.  Cases were selected from the donated 
brains of former athletes and military veterans who had a history of repetitive mild TBI.  
Eleven healthy control cases, ten early stage (Stage I/II), and nine late stage (Stage III/IV) 
CTE cases were selected for analysis.  Tissue sections of the anterior and posterior 
cingulate of each case were stained for microglia, reactive astrocytes, and macrophages 
using IBA-1, GFAP, and CD68 markers.  The percent area stained of each section was 
calculated to compare inflammatory cell density across progressive stages of the disease.  
Analysis showed a significant thinning of the corpus callosum of Stage III/IV CTE cases 
compared to normal controls.  There was a significant decrease in microglia and reactive 
astrocytes of both the anterior and posterior portions of the corpus callosum in both early 
and advanced stage CTE cases compared to healthy controls. Corpus callosum thickness 
was significantly decreased in advanced stage (III-IV), but not early stage (I-II) disease. 
Overall, this suggests that neuroinflammation is decreased in the corpus callosum 
in CTE despite marked degeneration.  Repetitive mild TBI might impair mechanisms of 
brain inflammation and repair. 
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INTRODUCTION 
 
 Due to the increased attention given to concussive head injuries sustained in 
contact sports and military combat, more people are becoming aware of the long-term 
dangers of mild traumatic brain injury (mTBI).  Participants of many contact sports 
including, but not limited to, American football, rugby, boxing, ice hockey, and lacrosse, 
are at risk of suffering head trauma that could have life-long effects.  In addition to 
athletes, it has been estimated that 20% of the 2.3 million American military servicemen 
and women that have been deployed since 2001 may have suffered from TBI at some 
point (Goldstein et al., 2012).  According to the Center for Disease Control (CDC), at 
least 1.7 million TBIs occur each year either as an isolated injury or along with other 
injuries.  Of those 1.7 million cases, over 52,000 die and almost 300,000 are hospitalized. 
In addition, there are many more cases of TBI that go unreported and do not receive the 
proper medical attention.  Injuries are typically a result of an impact or blow to the head 
and may result in serious disturbances in normal brain functioning.  
At the cellular level, there is an inflammatory cascade initiated in the brain as a 
result of the injury, and activated cells work to remove damaged tissue and protect 
healthy tissue.  This inflammatory cascade is partially responsible for many of the short-
term consequences of TBI, including headaches and temporary amnesia (Mayer, Huber, 
& Peskind, 2013).  While the initial symptoms of head trauma are better understood, little 
is known about what effect these types of concussive injuries can have on the brain years 
down the road.  Many studies are being conducted to look at the relationship between 
moderate to severe TBI and neurodegenerative disorders, including Alzheimer’s disease 
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(AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS), among others 
(Giunta et al., 2012;  Gavett, Stern, Cantu, Nowinski, & McKee, 2010).  This paper, 
however, aims to focus on the relationship between mild TBI and a disease that has 
gained much more attention around the world in the last decade: chronic traumatic 
encephalopathy (CTE).  Specifically, this paper examines the role of lingering 
inflammation in the progression of CTE.  It is known that an inflammatory response is 
initiated after injury and protective cells called microglia are activated to remove the 
damaged tissue (Mayer et al., 2013).  What is not known, however, is how long the 
inflammatory response persists and what detrimental effects it can have long-term on the 
brain.  
 
TRAUMATIC BRAIN INJURY 
Traumatic brain injury represents a spectrum of injury ranging from mild to 
severe.  While moderate to severe TBI can result in harmful brain injury, mild TBI may 
or may not result in a concussion.  The degree of injury can be crudely scored using the 
Glascow Coma Scale (GCS) where mild TBI has a high GCS (13-15) and includes 
concussions (Steyerberg et al., 2008).  Concussion is defined as a transient disturbance of 
neurological function following a mild traumatic injury (McCrory et al., 2009). This can 
manifest as a variety of physical, emotional, and cognitive symptoms, including 
temporary loss of consciousness followed by headaches, nausea, dizziness, blurred 
vision, and often memory loss to some extent. Some individuals may have more serious 
consequences, including cognitive deficits that impede their ability to communicate 
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appropriately.  According to the American Speech-Language-Hearing Association 
(ASHA), they may have difficulty with spelling, writing, reading, and understanding 
certain words.  Others may have problems with memory, reasoning, and problem solving.  
Internally, the immediate effects of TBI include neuronal cell injury and cell 
death, disruption of the blood brain barrier, mitochondrial dysfunction, and ionic and 
neurotransmitter homeostatic dysfunction.  These effects can last for days, weeks, or even 
months, impeding a full recovery to normal function.  In addition, the injury results in 
activation of a neuroinflammatory cascade.  Within minutes, the resident immune cells of 
the brain, called microglia, are activated and undergo a physical transformation that 
includes hypertrophy and dendritic thickening, in order to respond to the damage, fight 
infection, and protect healthy tissue (Giunta et al., 2012). 
Typically, the initial neuronal damage is found at the focal point of injury, 
however several studies found that evidence of inflammation and neuronal cell death can 
be found in distant brain regions.  One study used the positron emission tomography 
(PET) ligand [11C](R)PK11195 to analyze areas of activated microglia as a marker of 
inflammation (Ramlackhansingh, et. al., 2011).  This PK ligand binds to a translocator 
protein that is expressed by the mitochondria of activated microglia.  Interestingly, 
chronic microglial activation was not necessarily found in areas of focal brain injury.  
Instead, this study found that PK binding in brains affected by TBI was significantly 
higher compared to controls in several brain regions that were distant from the initial 
focus of injury.  These findings make it even more difficult to predict the long-term 
consequences of neuroinflammation resulting from a head injury.   
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White matter degeneration and axonal injury following TBI is common, most 
often involving the larger white matters structures in the brain such as the corpus 
callosum, a large white matter bundle connecting the two hemispheres of the brain that is 
particularly vulnerable to mechanical forces in concussive injury, and fornix. Researchers 
have found that even a single incident of trauma can lead to significantly larger ventricle-
to-brain ratios (VBR) and smaller fornix-to-brain ratios (FBR), as well as significantly 
decreased area of the corpus callosum compared to controls with no history of TBI  
(Gale, Johnson, Bigler, & Blatter, 1995).   
 
THE ROLE OF MICROGLIA FOLLOWING TRAUMATIC BRAIN INJURY 
 Microglia are the resident immune cells of the central nervous system and are the 
primary mediators of the brain’s innate immune response to infection, injury and disease.  
These cells constantly monitor tissue in the brain for any potential harmful or noxious 
substances and respond to anything signaling cell damage.  If anything is detected, 
microglia are responsible for clearing cellular debris and toxic materials by phagocytosis 
(Loane & Byrnes, 2010). In order to determine if something is harmful, microglia carry a 
set of pattern recognition receptors (PRRs) on their cell surface that recognize and 
respond to certain elements released by damaged cells and pathogens.  These elements 
are known as pathogen-associated molecular patterns (PAMPs) and damage-associated 
molecular patterns (DAMPs).  For example, microglia are highly responsive to adenosine 
triphosphate (ATP), glutamate, and certain cytokines as they are typically released by 
injured neurons (Aguzzi, Barres, & Bennett, 2013). 
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An area that requires more research with regards to the development of 
neurodegenerative diseases later on in life is the differential activation of microglia in 
response to injury.  When a microglia becomes activated, it can follow one of two 
pathways, becoming either pro- or anti-inflammatory.  Classical activation results in 
formation of the M1 phenotype, responsible for promoting inflammation, extracellular 
matrix (ECM) destruction, and apoptosis.  Initial activation is beneficial, however chronic 
activation leads to tissue injury and cell death (“Macrophage Activation,” 2004).  M1 
microglia can be activated in several ways, one of which is binding of bacterial 
lipopolysaccharide (LPS) to the microglial cell surface, indicative of a pathogenic 
bacterial infection that needs to be eradicated.  The classical activation pathway can also 
be initiated via detection of elements associated with cell damage and death, notably ATP 
and glutamate, as seen in head trauma (Aguzzi et al., 2013).  
Once activated, a series of pro-inflammatory cytokines are released into the 
surrounding environment, including nitric oxide (NO), tumor necrosis factor (TNFα), 
interleukins 6 and 12 (IL-6 and IL-12), as well as harmful free radicals that generate 
reactive oxygen species (ROS) and reactive nitrogen species (RNS).  The release of 
TNFα is notable due to its pro-apoptotic tendencies.  In addition to cytokines, 
chemokines are also released to attract leukocytes such as neutrophils, dendritic cells, and 
natural killer cells to the site of injury.  Degradation of the extracellular matrix occurs as 
M1 microglia release proteolytic enzymes that degrade collagen, elastin, and fibronectin 
(Saijo & Glass, 2011; Sharma & Parvathy, 2007).  Studies have found evidence that 
leukocyte migration elicited by M1 activation floods the surrounding tissue with 
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inflammatory mediators, pro-apoptotic factors, and matrix degrading proteases that can 
have toxic consequences on the neurons, leading to cell death.  For example, one study 
found that exposure of microglia to myelin in a cell culture, imitating damaged myelin 
debris in the brain, resulted in the release of NO, TNFα, and glutamate, with subsequent 
neuronal death (Johnson et al., 2013).   
 
 
Figure 1: Differential Activation of Microglia: Red arrows show the classical, pro-
inflammatory activation of microglia, while the green arrows show the alternative, anti-
inflammatory activation pathway. 
 
 
 	  	  
	  	  	  	  	  	  	  	  
 
 
The alternative activation pathway, known as M2 activation, works to resolve 
inflammation, promotes cell proliferation, and facilitates wound healing.  Presence of 
interleukins 4 and 13 (IL-4 and IL-13) activates the alternative pathway and, like the M1 
pathway, results in the release of chemokines that attract leukocytes to the site of injury.  
M2 microglia differ from M1, however, by their release of anti-inflammatory mediators 
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such as interleukin 10 (IL-10) and transforming growth factor beta (TGFβ).  M2 
microglia also directly produce fibronectin, an ECM constituent.  Various other factors 
released by M2 microglia, including platelet-derived growth factor (PDGF), insulin-like 
growth factor (IGF), and vascular endothelial growth factor (VEGF), all contribute to cell 
proliferation and angiogenesis, aiding in tissue repair and wound healing (Aguzzi et al., 
2013).   
When traumatic injury to the brain occurs, microglia are alerted of the physical 
damage to the neurons by responding to extracellular ATP and glutamate released by 
injured cells. Upon activation, microglia proliferate and migrate to the primary site of 
damage and interconnect their dendrites to form a physical barrier between the damaged 
and healthy neuronal tissue within hours of injury. In the normal response to tissue 
damage, studies have shown that classically activated microglia release pro-inflammatory 
mediators aimed at clearing the damaged tissue, followed by activation of alternative M2 
microglia that reduce the inflammation and protect the healthy tissue (Loane & Byrnes, 
2010).  However, as previously discussed, chronic activation of M1 microglia can 
eventually lead to neurotoxicity and cell death, a possible explanation for the delayed 
neurodegeneration often seen in those who have experienced repetitive head trauma.   
Researchers studying inflammation in spinal cord injuries (SCI) found that, while 
both M1 and M2 microglia were present at the site of SCI, M1 were present at a much 
higher degree.  They also found that when isolated M2 microglia were injected directly 
into the SCI, expression of M2-associated genes actually decreased, suggesting that the 
environment surrounding a central nervous system injury may suppress expression of the 
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M2 phenotype.  More research must be done to establish why these M1 microglia 
become chronically activated and why they predominate over the neuroprotective M2 
microglia (Aguzzi et al., 2013).   
 
TBI-RELATED DEMENTIA 
 There have been many studies linking moderate to severe TBI to an increased risk 
of several neurodegenerative diseases later in life, including AD, PD, and ALS, among 
others.  One group of researchers studied the relationship between TBI and the 
development of AD, arguing that the inflammatory response to TBI disrupted the balance 
between amyloid-beta (Aβ) protein anabolism and catabolism, eventually leading to a 
buildup of the hallmark Aβ protein in the brain (Giunta et al., 2012).  That same study 
found that the inflammatory-based effects and progression of TBI was still active in 
humans up to 17 years after the initial injury.  The fact that markers of inflammation and 
damage can be found up to 17 years later in affected neuronal areas leads researchers to 
believe that brain tissue continues to suffer the consequences of a traumatic injury years, 
even decades later, and may be the link between head trauma and neurodegenerative 
disease later in life.   
 
CHRONIC TRAUMATIC ENCEPHALOPATHY 
One disease that is rapidly gaining more and more global attention is chronic 
traumatic encephalopathy (CTE).  First documented in 1928 as “dementia pugilisitica,” 
CTE is a neurodegenerative disorder caused by repetitive trauma to the head.  Dr. 
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Harrison Stanford Martland studied several boxers who were experiencing what he called 
“punch drunk” syndrome, characterized by cognitive and motor deficits.  Upon autopsy, 
the brains of these boxers were found to have a distinct accumulation of the protein tau, 
which was attributed to repeated blows to the head sustained during their careers (Stern et 
al., 2011).  Years later, other studies found that this neuropathological pattern of tau 
accumulation was not limited to boxers, but was also found in other athletes and 
individuals who experienced TBI often. The disease then became known as chronic 
traumatic encephalopathy in order to describe the neurodegeneration associated with 
repetitive head trauma.   
Numerous recent cases of CTE have been described in former professional 
football players in the National Football League (NFL).  Some retired players begin 
experiencing memory and behavioral problems years after playing football.  Studies of 
former NFL players have found that the mortality rate from neurodegenerative diseases is 
up to three times higher than the general population (Gardner, Iverson, & McCrory, 
2013), and players over 50 years of age are five times more likely to have dementia than 
the national average for men in that age group (Lehman, Hein, Baron, & Gersic, 2012).  
Autopsies of several former NFL players have revealed the characteristic tau 
accumulation in specific neuronal areas indicative of CTE, as well as diagnostic findings 
of several other neurodegenerative diseases also correlated with head trauma.  Many 
players have been diagnosed in life with AD, dementia, depression, and CTE.  
Unfortunately, diagnosis of this disease can only be made with certainty upon death 
(McKee et al., 2009).   
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Military personnel are at an increased risk of developing the disease as well due to 
exposure to explosive blasts sustained while deployed.  One study mimicked this blast 
neurotrauma using mice and discovered that blast-exposed mice demonstrated hallmark 
signs of CTE, including tau protein hyperphosphorylation, myelinated axonopathy, 
chronic inflammation, and neurodegeneration (Goldstein et al., 2012).  This 
neuropathology was seen in mice as quickly as two weeks after exposure to a single blast.  
Cognitive tests also showed that the blast-exposed mice developed functional deficits in 
spatial memory and learning, as well as slowed axonal conduction, that was evident up to 
a month after blast exposure.    
 
CLINICAL PRESENTATION 
The clinical symptoms of CTE can mimic AD or other forms of dementia.  
However, some distinguishing features are beginning to be explored. For instance, as 
opposed to AD, which has an average onset at about 60 years of age and presents initially 
with memory problems, CTE presents earlier in life, typically in one’s 40s, and initially 
involves executive dysfunction, such as problems with judgment, reasoning, impulse 
control, and aggression.  Difficulties with problem solving and concentration progress to 
short-term memory impairment, aggression and explosivity, depression and mood 
swings, and eventually dementia. Many affected individuals feel paranoia, intense 
anxiety, and even suicidal thoughts.  Parkinsonism and motor deficits are common 
symptoms as well (Stern et al., 2011). 
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PATHOLOGICAL FEATURES OF THE DISEASE 
 Grossly, progression of the disease results in cerebral atrophy and reduction in 
brain weight, enlargement of the lateral and third ventricles, as well as thinning of the 
corpus callosum and other white matter structures (McKee et al., 2009).  The corpus 
callosum (CC) is the largest connective pathway in the human brain.  More than 200 
million nerve fibers compose the CC and serve to connect the left and right hemispheres 
of the brain.  In order to coordinate movement or process complex information, the 
hemispheres must be able to communicate with each other, thus any thinning or loss of 
the CC is very detrimental (“Corpus Callosum Disorders,” 2009).  Neuronal cell loss is 
common in CTE and contributes to the visible atrophy of several medial temporal lobe 
structures and the mammillary bodies, as well as pallor and discoloration of the substantia 
nigra.  The substantia nigra is an important motor center in the brain and is the primary 
site of degeneration in PD, a disease characterized by motor dysfunction, muscular 
rigidity, and tremors (Frank, Pari, & Rossiter, 2006).  Disruption of the substantia nigra 
may explain the symptoms of Parkinsonism and motor deficits commonly seen in the 
later stages of CTE.   
At the cellular level, the prominent pathology of CTE is a distinct buildup of the 
abnormal hyperphosphorylated tau protein in the brain.  This abnormal tau accumulates 
within neuronal processes, glial cells, and within neurons as neurofibrillary tangles 
(NFTs).  Tau is a microtubule-binding protein normally found in the brain that becomes 
insoluble when hyperphosphorylated and forms NFTs commonly associated with various 
forms of dementia (Morris, Maeda, Vossel, & Mucke, 2011).  This tau buildup can begin 
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months or years after initial injury and can continue for several years after that.  Tau 
NFTs are seen in other neurodegenerative diseases as well, notably in AD, but the pattern 
of deposition is distinct.  In CTE, tau accumulation is commonly found in dense patches 
in the superficial layers of the cortex, in the depths of the sulci, and in a perivascular 
pattern, as seen in Figure 2 (McKee et al., 2009; Gardner et al., 2013).   
 
Figure 2: Tau Deposition in Normal Brain vs. Stage IV CTE: This image shows the 
high levels of abnormal tau protein deposition (brown staining) in advanced stage CTE, 
especially in the superficial layers of the neocortex and in the depths of the sulci. 
 
 
 
Also, NFTs are found in the hippocampus, amygdala, hypothalamus, and various 
areas of the frontal and temporal lobes.  Infiltration of the amygdala and hippocampus 
with abnormal tau is of importance because of the prominent roles that these structures 
© Ann McKee, MD, Boston University Center for the Study of Traumatic Encephalopathy.    	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play in regulating emotion and memory, respectively.  This tau accumulation is thought 
to contribute to the neuronal cell loss seen in these structures in the later stages of the 
disease (Stern et al., 2011).   
Several white matter structures, most notably the CC, can accumulate a 
significant amount of irregular tau protein as the disease progresses. While the amount of 
irregular protein is generally much higher in the adjacent gray matter than in the white 
matter, white matter tau deposition can cause serious disruptions in communication 
pathways (McKee et al., 2009; Kraus et al., 2007).  
 
STAGES OF THE DISEASE 
The progression of CTE can be divided into four stages of severity based on level 
of protein deposition and cerebral atrophy (McKee et al., 2013; Wexler, 2013).   
• Stage I – Clinically, the individual presents with few symptoms other than 
headaches and some difficulties with concentration.  Post-mortem examination of the 
brain reveals some isolated spots of tau deposition in the frontal lobe, mostly deep in the 
sulcal depths.  Mechanical forces are transmitted and concentrated at the sulcal depths 
making them especially vulnerable to traumatic injury.  Otherwise, brains diagnosed with 
Stage I CTE are unremarkable. 
• Stage II – Clinically, symptoms worsen and include depression, mood swings, 
aggression, and sometimes short-term memory impairments. Tau deposition increases in 
the frontal lobe of the brain as neurofibrillary tangles can be found in several layers of the 
cortex.  Tangles can also begin to be seen in several brain structures that are important for 
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emotion and memory including the amygdala, hypothalamus, hippocampus, and thalamus.  
Ventricular enlargement can also be seen.  
 
 
Figure 3: Gross Pathology of Normal Brain vs. Brain with Advanced CTE: This 
image shows the severe cerebral atrophy found in advanced CTE, where brain weight can 
reduced by as much as half. The enlargement of the lateral and third ventricles can also 
be seen. 
 
 	  
• Stage III – Clinically, affected individuals demonstrate cognitive impairment and 
problems with planning, organization, and judgment.  Depression and mood swings are 
much more common in this stage.  Neuropathologically, tau deposition is increased in the 
frontal lobe and expanded into the temporal lobe.  Cerebral atrophy has begun with 
increased dilation of the lateral and third ventricles.  
© Ann McKee, MD, Boston University Center for the Study of Traumatic Encephalopathy.    	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• Stage IV – The most severe stage of the disease presents clinically with severe 
loss of executive function and cognitive dysfunction.  Aggression, dementia, severe 
memory loss, and difficulties with attention and concentration are all common symptoms 
of this stage.  Suicidal thoughts, though less common, are possible.  There is significant 
cortical and white matter atrophy, as seen in Figure 3.  Microscopically, tau deposition 
involves much of the brain with substantial accompanying neuronal loss. 	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SPECIFIC AIMS OF THE PRESENT STUDY 
 
Neuroinflammation plays a role in a variety of neurodegenerative diseases and 
has been shown to occur following traumatic brain injury.  Inflammation following 
trauma acutely can be beneficial for recovery.  However, chronic inflammation can be 
damaging to neuronal cells, and it is possible that it plays a role in the degeneration and 
neuronal death seen in CTE.  Thus, we hypothesize that in subjects with CTE and a 
history of repetitive mTBI there is increased chronic inflammation years after the trauma 
and in regions known to be affected acutely.  We quantified the chronic markers of 
neuroinflammation, including microglia and reactive astrocytes, found in neuronal tissue 
of individuals diagnosed with varying stages of CTE. 
   
Aim 1:  To determine whether levels of neuroinflammation are altered in subjects 
with CTE vesrsus control subjects using immunohistochemistry for microglia (IBA-1), 
reactive astrocytes (GFAP), and macrophages (CD68) in regions known to be affected by 
acute mTBI (anterior and posterior corpus callosum and thalamus).  
Aim 2:  To determine whether degeneration of the corpus callosum is increased in 
subjects with CTE versus control subjects with no history of repetitive mTBI and to 
correlate any degeneration with the level of neuroinflammation determined in Aim 1. 
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METHODS 	  
COMPILING	  THE	  CASE	  LIST	  FOR	  ANALYSIS	  
	  
The Boston University Center for the Study of Traumatic Encephalopathy (CSTE) 
established a Brain Bank at the Veterans Administration Medical Center in Bedford, MA 
in 2008 where the brains of former athletes and military veterans are donated post-
mortem for research purposes.  All cases were selected from the Brain Bank inventory 
list that provided information about each individual case, including age, sport played and 
career duration, number of concussions, cause of death, and neuropathological diagnoses.  
These characteristics were all taken into account when compiling the selected case list for 
analysis.  Cases of older age and longer career duration were chosen when possible.  
Cases with any neurodegenerative disorders other than CTE, such as AD, ALS, and PD, 
were eliminated to avoid any potential confounding variables.   
A total of 30 cases were selected, all male, ranging in age from 23 to 87 years old. 
Ten CTE Stage I or II disease cases (3 Stage I, 7 Stage II) and nine CTE Stage III or IV 
disease cases (3 Stage III, 6 Stage IV) were analyzed.  Of those nineteen cases, three 
were professional NHL hockey players and sixteen had played football at some level, 
including twelve who played in the NFL.  The average career duration beginning in high 
school for early stage CTE cases was 12.3 years, and 17.25 years for late stage CTE. It is 
important to note that many individuals in this study only reported diagnosed 
concussions, while admitting that they suffered many more undiagnosed subconcussive 
and concussive blows to the head throughout their careers. Eleven control cases with no 
reported history of contact sports or military activity were used for comparison.  
	  18 
Table 1.  Details of Selected Case List:  Control cases were chosen in order to minimize 
history of head trauma or early death due to disease.  CTE cases that were selected played 
sports for at least several years and contained information regarding concussive history.  
 
Case 
CTE 
Stage Age Sport Played 
Career Duration 
(Years) 
# Of 
Concussions 
BVAX 140 0 67 N/A N/A 0 
BVAX 142 0 74 N/A N/A 0 
BVAX 146 0 72 N/A N/A 0 
BVAX 278 0 69 N/A N/A 0 
BVAX 85 0 61 N/A N/A 0 
BVAX 255 0 92 N/A N/A 0 
BVAX 258 0 57 N/A N/A 0 
BVAX 282 0 87 N/A N/A 0 
BVAX 288 0 63 N/A N/A 0 
BVAX 310 0 93 N/A N/A 0 
BVAX 350 0 93 N/A N/A 0 
Avg: 0 75.2  -   -  0 
      SLI-43 1 23 NFL 9  -  
SLI-45 1 34 Football 12 0 
SLI-79 1 56 Football 11 2 
SLI-36 2 45 NHL 21 3 or 4 
SLI-63 2 49 Football, Hockey 8 7 
SLI-69 2 59 NHL 14 1 
SLI-76 2 28 NHL 10 >20 
SLI-84 2 65 Football 20 >30 
SLI-85 2 56 Football 5 10 
SLI-22 2 87 Football 13 3 or 4 
Avg: 1.7 50.2  -  12.3 8.5 
      SLI-20 3 64 Football, Boxing 13 2 
SLI-53 3 56 Football 15 20 
SLI-67 3 50 NFL 19 >10 
SLI-14 4 82 NFL 18 16 or 17 
SLI-56 4 75 NFL 20 0 
SLI-64 4 80 Football 23 1 
SLI-73 4 84 Football 20 20-30 
SLI-78 4 81 NFL  -  >100 
SLI-89 4 64 Football 10 4 
Avg: 3.6 70.6  -  17.25 20.4 
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TISSUE STAINS AND SECTIONS 
After the cases were chosen, tissue sections of each case were cut and stained for 
the following regions: 1) Anterior corpus callosum and cingulate gyrus at the level of the 
amygdala; 2) Posterior corpus callosum and gyrus at the level of the lateral geniculate 
nucleus, and 3) Thalamus at the level of the subthalamic nucleus.  The neuronal areas of 
primary interest in this study were the anterior and posterior cingulate, specifically the 
white matter of the corpus callosum.  Three sections of each neuronal area were cut and 
mounted on glass slides to be stained using three different stains: Iba-1, GFAP, and 
CD68.  The Iba-1 (ionized calcium-binding adaptor molecule 1) stain contains an anti-
Iba-1 antibody that binds to the Iba-1 gene expressed specifically by microglia in the 
brain.  Upon microglial activation due to trauma and inflammation, Iba-1 becomes up 
regulated.  The GFAP stain binds to the glial fibrillary acidic protein (GFAP) found 
specifically in astrocytes, a type of glia, found in the central nervous system.  Finally, the 
CD68 stain contains an anti-CD68 antibody that binds to CD68, a transmembrane 
glycoprotein that is highly expressed by microglia and macrophages in the brain. These 
stains were chosen because of their high affinity for microglia, reactive astrocytes, and 
macrophages, allowing areas of neuroinflammation to be seen and quantified.   
 
QUALITATIVE AND QUANTITATIVE ANALYSIS 
 To begin the qualitative analysis, all slides were staged based on stain intensity.  
Under the microscope, at varying magnifications from 4x to 20x, each slide was given a 
grade of inflammatory severity ranging from one (only rare cells stained) to three (many 
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cells stained).  Within each slide, there were three distinct areas: corpus callosum, 
cingulate cortex, and deep white matter.  Each area within each slide was independently 
staged for each of the three stains, blinded to the subject history.  In addition, quantitative 
measurements of the staining area within the corpus callosum were also taken.  Using the 
SPOT image capture software, three images of the corpus callosum at a magnification at 
10x were captured, with each image capturing a distinct area of the callosum.  Images 
were then analyzed using ImageJ software.  All images were converted into a black and 
white 8-bit image and threshold was automatically adjusted to maintain consistency, with 
the exception of a few tissue slides with abnormal background color.  The percent area 
taken up by the stain was then calculated for each image, and the average area was 
determined for each region.  
 Measurements of the thickness of the corpus callosum were performed on Luxol, 
hematoxylin and eosin stained sections using the SPOT software.  Images of both the 
anterior and posterior callosum at a 2x magnification were taken and then the callosum 
was measured at three points in order to obtain an accurate average of the width.  As 
described previously, the width of the callosum was measured at its junction with the 
cingulate gyrus, at the cut midline of the CC, and at the midpoint between these two 
points (Johnson et al., 2013).  
 All statistical analyses and tests, including upaired t-tests and one-way ANOVAs 
testing for differences in cell staining areas and corpus callosum thickness, were 
completed using GraphPad InStat software.   
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RESULTS 	   	  	   A total of 30 cases were analyzed to compare the level of chronic inflammation 
found in specific brain areas in those diagnosed with CTE compared with normal, healthy 
controls.  There were eleven control cases that reported no history of head trauma, all 
male, ranging in age from 57 to 93 (Mean = 75.27).  Ten Stage I/II and nine Stage III/IV 
CTE cases were selected, all male, ranging in age from 23 to 87 (Mean = 59.89).  Three 
separate stains were used to visualize inflammatory cells, IBA-1 (microglia), GFAP 
(astrocytes), and CD68 (macrophages).  Cell area was measured by calculating the 
average percent area stained in each region. 
 When comparing the healthy controls to those diagnosed with Stage I/II CTE, 
there was a significant decrease in cell area of the anterior CC in Stage I/II subjects seen 
in all stains (IBA-1 p = 0.0063; GFAP p = 0.0035; CD68 p = 0.0065).  A similar 
significant decrease was also seen in the posterior CC for IBA-1 (p = 0.0228) and GFAP 
(p = 0.0427).  CD68 staining area was also decreased, but failed to reach significance (p 
= 0.2293).  The exact percent area values can be found in Table 1.   
 There was a more pronounced decrease in microglia, reactive astrocyte, and 
macrophage area in both the anterior and posterior CC in advanced stage CTE when 
compared to healthy controls.  The percent area stained in the anterior CC was 
significantly lower in Stage III/IV subjects in the IBA-1 (p = 0.0002) and GFAP stains (p 
= 0.0058), while the CD68 stain just barely failed to show significance (p = 0.0663).  
Inflammatory cell area in the posterior CC was significantly lower in the Stage III/IV 
CTE subjects compared to controls in IBA-1 (p = 0.0034) and CD68 stains (p = 0.0046, 
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but failed to reach significance in GFAP staining (p = 0.1598). Exact values can be found 
in Table 2. 
Figure 4: A Comparison of Microglial Density in Controls vs. Stage I/II CTE:  The 
percent area value of inflammatory cell staining is decreased in the anterior and posterior 
portions of the CC in early stage CTE subjects compared to controls.  A) Table and 
corresponding bar graph showing the percent area stained in the anterior portion of the 
CC.  B) Table and corresponding bar graph showing the percent area stained in the 
posterior portion of the CC.   
 
 	  	  	  	  	  	  	   	  	  	  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stain Control  
CC % 
Stage I/II  
CC % 
Significance, 
 P-value 
IBA-1 5.45 ± 0.673 3.181 ± 0.371 0.0063 
GFAP 5.911 ± 1.508 1.043 ± 0.305 0.0035 
CD68 4.114 ± 0.229 2.92 ± 0.37 0.0065 
Stain Control  
CC % 
Stage I/II  
CC % 
Significance, 
 P-value 
IBA-1 3.366 ± 0.319 2.392 ± 0.308 0.0228 
GFAP 0.902 ± 0.37 0.164 ± 0.074 0.0427 
CD68 5.024 ± 0.293 4.487 ± 0.673 0.2293 
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Figure 5:  A Comparison of Microglial Density in Controls vs. Stage III/IV CTE: 
The percent area value of inflammatory cell staining is decreased in the anterior and 
posterior portions of the CC in late stage CTE subjects compared to controls.  A) Table 
and corresponding bar graph showing the percent area stained in the anterior portion of 
the CC.  B) Table and corresponding bar graph showing the percent area stained in the 
posterior portion of the CC.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stain Control  
  CC % 
Stage III/IV  
CC % 
Significance, 
 P-value 
IBA-1 5.45 ± 0.673 1.938 ± 0.337 0.0002 
GFAP 5.911 ± 1.508 1.051 ± 0.477 0.0058 
CD68 4.114 ± 0.229 3.76 ± 0.358 0.2002 
 Stain Control  
CC % 
Stage III/IV 
CC% 
Significance, 
 P-value 
IBA-1 3.366 ± 0.319 1.942 ± 0.301 0.0034 
GFAP 0.902 ± 0.371 0.458 ± 0.086 0.1598 
CD68 5.024 ± 0.294 3.518 ± 0.423 0.0046 
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Figure 6:  Control vs. Stage III/IV CTE, Anterior Corpus Callosum: Slides 
comparing the microglial density of the anterior corpus callosum in selected control and 
Stage III/IV CTE cases across all stains.  There is a significant reduction in microglial 
density in late stage CTE compared to control in IBA-1 and GFAP stains.  While not 
statistically significant, there was a reduction in density in late stage CTE seen in CD68 
staining.  A) Control case, IBA-1 stain; B) Stage IV CTE, IBA-1; C) Control, GFAP 
stain; D) Stage IV CTE, GFAP; E) Control; CD68 stain; F) Stage III CTE, CD68. 
     Control        Stage III/IV CTE 
	  	  
	  
	  
A	   B	  
C	   D	  
F	  E	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   After measuring the thickness of both the anterior and posterior portions of the 
corpus callosum in each section, unpaired t-tests showed a significant decrease in both 
anterior and posterior CC thickness in Stage III/IV CTE cases compared to normal 
controls (p = 0.0319 and p = 0.0034, respectively).  There was no thickness difference 
found when comparing controls to Stage I/II CTE cases in either the anterior or posterior 
section of CC (p = 0.3604 and p = 0.4547, respectively).  Though not quite statistically 
significant, there was a reduction in thickness of the anterior CC in advanced CTE 
compared to early stage disease (p = 0.0841).  No statistical difference was found in 
posterior CC thickness between Stage I/II and Stage III/IV CTE cases.   
 
Table 2. A Comparison of Corpus Callosum Thickness: There was a significant 
decrease in the average thickness of the anterior CC, as well as a marked decrease in 
posterior CC thickness, in late stage CTE cases compared to controls. All measurements 
are in µm. 	   	  	  
 
 
 
 	  	  
 Control Stage I/II CTE Stage III/IV CTE 
Anterior CC 5198 ± 260 5040 ± 326 4312 ± 360 
Posterior CC 4268 ± 182 4212 ± 467 3908 ± 125 
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DISCUSSION 
 
 While it is known that traumatic brain injury results in the immediate activation of 
an innate immune response, including initiation of a neuroinflammatory pathway, little is 
known about the long-term consequences of repetitive mild TBI with regards to 
inflammation.  Here it is shown that inflammatory cells are decreased in the anterior and 
posterior corpus callosum in the brains of individuals diagnosed with late stage CTE 
compared to normal, healthy controls.  Also, the thickness of the corpus callosum, both 
anterior and posterior, decreased in late stage CTE compared to controls. 
Many studies have shown that white matter degeneration is common as CTE 
progresses due to the unique biomechanical forces imposed on the brain during TBI 
(Gardner et al., 1995; Kraus et al., 2007).  For example, one study found structural 
disruption of the white matter after TBI, including degeneration of the axon and 
surrounding myelin, demonstrated by decreased Luxol fast blue staining, a stain specific 
for observing myelin (Johnson et al., 2013).  That same study found Luxol fast blue-
positive fragments in areas of white matter where microglia were present, indicating 
active phagocytosis of myelin.  This evidence shows that TBI not only induces physical 
damage to axons of white matter, but that it also results in pathological cellular damage 
as well, leading to degeneration. 
The corpus callosum is particularly susceptible to physical damage from shearing 
forces due to its location between the two hemispheres.  If disrupted, information is 
unable to travel between both sides of the brain and the ability to make coordinated 
movements and complex thought processes might be affected.  Because of susceptibility 
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to mechanical damage, many individuals suffering from CTE show thinning of the corpus 
callosum (Jordan, 2013), a finding that is duplicated in this present study with the first 
quantitation of this effect.  There was no significant difference in the thickness of either 
the anterior or posterior CC between healthy controls and brains diagnosed with Stage 
I/II CTE.  Typically in earlier stages of the disease, outer cortical regions are initially 
affected, while degeneration of the corpus callosum is seen in later stages of the disease.  
Cases diagnosed with Stage III/IV CTE had a significantly thinner anterior CC compared 
to controls and, while not quite statistically significant, a reduction in the thickness of the 
posterior CC was seen as well.  It has been noted qualitatively that there is more severe 
atrophy and thinning in the anterior portion of the CC compared to the posterior portion 
(McKee et al., 2009).  These quantitative results support this observation and show that 
there is a 17% reduction of the anterior CC compared to 9% reduction of the posterior CC 
in late stage CTE compared to controls. 
Perhaps the most interesting finding of this study is the fact that microglial area 
actually decreased in the later stages of CTE, while the level of white matter degeneration 
measured by CC thinning increased.  The cases diagnosed with late Stage CTE have a 
longer average athletic career and suffered more concussions on average than early stage 
CTE and control cases, therefore it is not surprising to see the classic white matter 
degeneration of the CC.  However, it is unusual that there is a significant decrease in 
inflammatory cells in both early and late stage CTE compared to controls in most stains 
across both the anterior and posterior CC.  White matter of the control cases had a 
significant number of inflammatory cells, which may a natural result of aging (Figure 7).  
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While not as statistically significant, there was a slight reduction in density in late stage 
compared to early stage CTE as well.  These results contradict previous studies in which 
the presence of neuroinflammatory markers and CC degeneration were positively 
correlated in diseases such as CTE (Johnson et al, 2013) and multiple sclerosis 
(Stadelmann, Wegner, & Brück, 2011).  It is possible that chronic activation has caused 
the microglia to “burn out” and dissipate while neurodegenerative properties continue. 
 
Table 3. A Comparison of Age Across Groups:  The mean age difference between 
normal controls and Stage I/II CTE cases was 25 years, and 4.6 years between controls 
and Stage III/IV cases. 
 
 
 
The normal aging process must be taken into account during analysis, as it is well 
known that microglia become increasingly activated with normal aging (Dilger & 
Johnson, 2008).  It has been suggested that the aging process can serve as a “primer” for 
microglia, making them more susceptible to subsequent activation by a triggering 
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stimulus.  This activation then leads to the release of excessive quantities of pro-
inflammatory mediators.  Our controls are 25 years older than the early stage CTE cases, 
and this may at least partially explain the apparent decrease in inflammatory cells in this 
group.  However, they are closer in age to the advanced stage CTE cases (4.6 years 
older), and therefore it is less likely to completely explain the decrease observed in these 
subjects.      
Previous evidence has suggested that chronic activation of microglia and other 
inflammatory markers are responsible for much of the neuronal death and degeneration 
seen in many neurodegenerative disorders, including CTE.  One theory that supports this 
is the idea of immunoexcitotoxicity, where hyperactive pro-inflammatory microglia 
predominate in the tissue and constantly flood the tissue with pro-inflammatory 
cytokines, proteases, and pro-apoptotic elements that lead to cell death (Blaylock & 
Maroon, 2011).  In a normal inflammatory reaction, these initial pro-inflammatory M1 
microglia would eventually give way to neuroprotective M2 microglia that aid in 
controlling the inflammation and repairing the tissue.  In immunoexcitotoxicity, however, 
this does not happen.  Evidence has suggested that an initial traumatic injury may prime 
the microglia, much as an allergic reaction does for other immune cells, to react much 
more strongly to a subsequent incident, making it a plausible theory for CTE. Chronic 
activation leads to increased levels of ROS, RNS, and lipid peroxidation products that 
cause decreased glutamate clearance, a trigger that activates even more pro-inflammatory 
microglia and continues a vicious cycle.  This constant release of pro-inflammatory 
cytokines and degradative enzymes may directly lead to the progressive cell death and 
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degeneration seen in CTE (Blaylock & Maroon, 2011).  It is possible that M1 microglia 
are increased and M2 are decreased in CTE leading to observed white matter 
degeneration. 
 	   	  	  	  	  
	  
	  
 
 
Another possible explanation to support these findings of decreased microglial 
cells in CTE is that the long-term, chronic activation of microglia causes the microglia to 
“burn out” as the disease progresses.  Additional studies might explore chronic 
immunoexcitotoxicity and its effect on microglial density to see if there is a correlation.  
A	  
B	   C	  
Figure 7: Magnified Images of 
Activated Microglia: These 
images taken at 20x magnification 
show highly active microglia in 
the anterior corpus callosum of 
healthy control cases.  The 
enlarged cell bodies and dendritic 
processes are clearly seen.   
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A study researching the link between repetitive TBI and the development of AD found 
that microglial density in the hippocampus and entorhinal cortex did increase in earlier 
stages of the disease, as expected, but actually then decreased in later stages while the 
level of neuritic plaques and NFTs continued to increase (Walker & Lue, 2007).  It is 
interesting that the pathological protein deposition continued in this case even though the 
level of inflammation appeared to subside.  With regards to the present study, additional 
staining for abnormal tau deposition should be done on the selected cases to see if the 
pattern of pathological tau deposition in the superficial cortex and white matter is 
affected at all by the apparent decrease in inflammation.	  
Another study found similar results in multiple sclerosis (MS), a demyelinating 
disorder of the central nervous system (Lassmann & van Horssen, 2011).  This study 
found that during the late stages of progressive MS, inflammation in the normal 
appearing white matter (NAWM) actually decreases while cognition continues to decline.  
Although CTE has been the focus of an increasing number of research studies in 
the last decade, more research must be done to answer the countless questions regarding 
this terrible disease.  It is still unknown exactly what type, frequency, or amount of 
trauma is needed to induce these pathological symptoms.  When considering the present 
study, future research should use a larger sample size and include cases with closer age-
matched controls to investigate a possible explanation for these findings.  The groups 
used in this study were of a relatively small size and may not be representative of the 
actual population.  
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Another potential area of research to be done is to stain the tissue sections to 
distinguish between classically and alternatively activated microglia.  Though the exact 
process is unknown, there is clearly an imbalance between these two types of microglia 
found in the brain after repetitive head trauma.  Normally, classically activated M1 
microglia respond immediately to the site of damage and causes inflammation in order to 
remove any potentially toxic debris and protect the healthy tissue, while subsequent 
activation of alternative M2 microglia works to reduce inflammation and repair any 
damage to the tissue.  However, sometimes after repeated incidents of trauma, M1 
microglia are continuously activated resulting in chronic inflammation and leukocyte 
infiltration, ECM destruction, and neuronal cell death.  The neuroprotective M2 microglia 
are dominated by M1 activation, therefore healthy tissue is vulnerable to the damaging 
effects of chronic inflammation.  Future studies should aim to establish a ratio of M1:M2 
microglia in areas of inflammation and degeneration to help elucidate any potential 
mechanisms of this imbalance.   
Overall, our understanding of the disease process in CTE is just beginning.  
Currently, CTE can only be diagnosed with certainty upon autopsy, and biomarkers in 
living individuals are urgently needed to enable both diagnosis and treatment.  
Understanding the pathogenesis of the disease process and the role of neuroinflammation 
will facilitate this.  
 
 
 
	  33 
REFERENCES 
 
Aguzzi, A., Barres, B. A., & Bennett, M. L. (2013). Microglia: Scapegoat, Saboteur, or  
Something Else? Science, 339(6116), 156–161. doi:10.1126/science.1227901 
 
Blaylock, R., & Maroon, J. (2011). Immunoexcitotoxicity as a central mechanism in  
chronic traumatic encephalopathy-A unifying hypothesis. Surgical Neurology 
International, 2(1), 107. doi:10.4103/2152-7806.83391 
 
CDC - Statistics - Traumatic Brain Injury - Injury Center. (2013). Retrieved February  
17, 2014, from http://www.cdc.gov/traumaticbraininjury/statistics.html 
 
Corpus Callosum Disorders. (2009). Retrieved February 17, 2014, from  
https://www.nodcc.org/index.php?option=com_content&task=view&id=12&Item
id=27 
 
Dilger, R. N., & Johnson, R. W. (2008). Aging, microglial cell priming, and the  
discordant central inflammatory response to signals from the peripheral immune 
system. Journal of Leukocyte Biology, 84(4), 932–939. doi:10.1189/jlb.0208108 
 
Frank, C., Pari, G., & Rossiter, J. P. (2006). Approach to diagnosis of Parkinson disease.  
Canadian Family Physician, 52(7), 862–868. 
 
Frequently Asked Questions  » Center for the Study of Traumatic Encephalopathy |  
Boston University. (2013). Retrieved February 17, 2014, from 
http://www.bu.edu/cste/about/frequently-asked-questions/ 
 
Gale, S. D., Johnson, S. C., Bigler, E. D., & Blatter, D. D. (1995). Nonspecific white  
matter degeneration following traumatic brain injury. Journal of the International 
Neuropsychological Society: JINS, 1(1), 17–28. 
 
Gardner, A., Iverson, G. L., & McCrory, P. (2013). Chronic traumatic encephalopathy  
in sport: a systematic review. British Journal of Sports Medicine, bjsports–2013–
092646. doi:10.1136/bjsports-2013-092646 
 
Gavett, B. E., Stern, R. A., Cantu, R. C., Nowinski, C. J., & McKee, A. C. (2010). Mild  
traumatic brain injury: a risk factor for neurodegeneration. Alzheimer’s Research 
& Therapy, 2(3), 18. doi:10.1186/alzrt42 
 
Giunta, B., Obregon, D., Velisetty, R., Sanberg, P. R., Borlongan, C. V., & Tan, J.  
(2012). The immunology of traumatic brain injury: a prime target for Alzheimer’s 
disease prevention. Journal of Neuroinflammation, 9(1), 185. doi:10.1186/1742-
2094-9-185 
	  34 
 
Goldstein, L. E., Fisher, A. M., Tagge, C. A., Zhang, X.-L., Velisek, L., Sullivan, J. A.,  
… McKee, A. C. (2012). Chronic Traumatic Encephalopathy in Blast-Exposed 
Military Veterans and a Blast Neurotrauma Mouse Model. Science Translational 
Medicine, 4(134), 134ra60–134ra60. doi:10.1126/scitranslmed.3003716 
 
Johnson, V. E., Stewart, J. E., Begbie, F. D., Trojanowski, J. Q., Smith, D. H., & Stewart,  
W. (2013). Inflammation and white matter degeneration persist for years after a 
single traumatic brain injury. Brain: A Journal of Neurology, 136(Pt 1), 28–42. 
doi:10.1093/brain/aws322 	  
Jordan, B. D. (2013). The clinical spectrum of sport-related traumatic brain injury.  
Nature Reviews Neurology, 9(4), 222–230. doi:10.1038/nrneurol.2013.33 
 
Kraus, M. F., Susmaras, T., Caughlin, B. P., Walker, C. J., Sweeney, J. A., & Little, D.  
M. (2007). White matter integrity and cognition in chronic traumatic brain injury: 
a diffusion tensor imaging study. Brain: A Journal of Neurology, 130(Pt 10), 
2508–2519. doi:10.1093/brain/awm216 
 
Lassmann, H., & van Horssen, J. (2011). The molecular basis of neurodegeneration in  
multiple sclerosis. FEBS Letters, 585(23), 3715–3723. 
doi:10.1016/j.febslet.2011.08.004 	  
Lehman, E. J., Hein, M. J., Baron, S. L., & Gersic, C. M. (2012). Neurodegenerative  
causes of death among retired National Football League players. Neurology, 
WNL.0b013e31826daf50. doi:10.1212/WNL.0b013e31826daf50 
 
Loane, D. J., & Byrnes, K. R. (2010). Role of Microglia in Neurotrauma.  
Neurotherapeutics  : The Journal of the American Society for Experimental 
NeuroTherapeutics, 7(4), 366–377. doi:10.1016/j.nurt.2010.07.002 
 
Macrophage Activation. (2004). Retrieved February 17, 2014, from  
http://www.rndsystems.com/cb_detail_objectname_SP04_MacrophageActivation.
aspx 
 
Mayer, C. L., Huber, B. R., & Peskind, E. (2013). Traumatic Brain Injury,  
Neuroinflammation, and Post-Traumatic Headaches. Headache: The Journal of 
Head and Face Pain, 53(9), 1523–1530. doi:10.1111/head.12173 	  
McCrory, P., Meeuwisse, W., Johnston, K., Dvorak, J., Aubry, M., Molloy, M., & Cantu,  
R. (2009). Consensus Statement on Concussion in Sport: the 3rd International 
Conference on Concussion in Sport held in Zurich, November 2008. British 
Journal of Sports Medicine, 43(Suppl 1), i76–i84. doi:10.1136/bjsm.2009.058248 	  
	  35 
McKee, A. C., Cantu, R. C., Nowinski, C. J., Hedley-Whyte, E. T., Gavett, B. E.,  
Budson, A. E., Stern, R. A. (2009). Chronic Traumatic Encephalopathy in 
Athletes: Progressive Tauopathy following Repetitive Head Injury. Journal of 
Neuropathology and Experimental Neurology, 68(7), 709–735. 
doi:10.1097/NEN.0b013e3181a9d503 
 
McKee, A. C., Stein, T. D., Nowinski, C. J., Stern, R. A., Daneshvar, D. H., Alvarez, V.  
E., Cantu, R. C. (2013). The spectrum of disease in chronic traumatic 
encephalopathy. Brain, 136(1), 43–64. doi:10.1093/brain/aws307 
 
Morris, M., Maeda, S., Vossel, K., & Mucke, L. (2011). The Many Faces of Tau. Neuron,  
70(3), 410–426. doi:10.1016/j.neuron.2011.04.009 
 
Ramlackhansingh, A. F., Brooks, D. J., Greenwood, R. J., Bose, S. K., Turkheimer, F. E.,  
Kinnunen, K. M., Sharp, D. J. (2011). Inflammation after trauma: microglial 
activation and traumatic brain injury. Annals of Neurology, 70(3), 374–383. 
doi:10.1002/ana.22455 
 
Saijo, K., & Glass, C. K. (2011). Microglial cell origin and phenotypes in health and  
disease. Nature Reviews Immunology, 11(11), 775–787. doi:10.1038/nri3086 
 
Sharma, J. N., Al-Omran, A., & Parvathy, S. S. (2007). Role of nitric oxide in  
inflammatory diseases. Inflammopharmacology, 15(6), 252–259. 
doi:10.1007/s10787-007-0013-x 	  
Stadelmann, C., Wegner, C., & Brück, W. (2011). Inflammation, demyelination, and  
degeneration — Recent insights from MS pathology. Biochimica et Biophysica 
Acta (BBA) - Molecular Basis of Disease, 1812(2), 275–282. 
doi:10.1016/j.bbadis.2010.07.007 
 
Stern, R. A., Riley, D. O., Daneshvar, D. H., Nowinski, C. J., Cantu, R. C., & McKee, A.  
C. (2011). Long-term Consequences of Repetitive Brain Trauma: Chronic 
Traumatic Encephalopathy. PM&R, 3(10, Supplement 2), S460–S467. 
doi:10.1016/j.pmrj.2011.08.008 	  
Steyerberg, E. W., Mushkudiani, N., Perel, P., Butcher, I., Lu, J., McHugh, G. S., …  
Maas, A. I. R. (2008). Predicting Outcome after Traumatic Brain Injury: 
Development and International Validation of Prognostic Scores Based on 
Admission Characteristics. PLoS Med, 5(8), e165. 
doi:10.1371/journal.pmed.0050165 
 
Traumatic Brain Injury (TBI). (2013). American Speech-Language-Hearing Association.   
Retrieved February 17, 2014, from 
http://www.asha.org/public/speech/disorders/tbi/ 
	  36 
Walker, D., & Lue, L.-F. (2007). Anti-inflammatory and Immune Therapy for  
Alzheimer’s Disease: Current Status and Future Directions. Current 
Neuropharmacology, 5(4), 232–243. doi:10.2174/157015907782793667 
 
Wexler, E. (2013). How CTE Affects the Brain – League of Denial: The NFL’s  
Concussion Crisis. FRONTLINE. Retrieved February 17, 2014, from 
http://www.pbs.org/wgbh/pages/frontline/sports/league-of-denial/the-four-stages-
of-cte/ 
  
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  37 
CURRICULUM VITAE 
	  38 
	  39 
